Clinical data | |
---|---|
Other names | PER977; N,N-bis-L-argininamide |
Routes of administration | Intravenous |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Onset of action | 10 min |
Duration of action | 24 hours |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C22H48N12O2 |
Molar mass | 512.708 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
Ciraparantag (aripazine) is a drug under investigation as an antidote for a number of anticoagulant (anti-blood clotting) drugs, including factor Xa inhibitors (rivaroxaban, apixaban and edoxaban), dabigatran, and heparins (including fondaparinux, low molecular weight heparins (LMWH), and unfractionated heparin).
Medical uses
Ciraparantag significantly reverses anticoagulation induced by a therapeutic dose of edoxaban within 10 minutes following injection. This return to normal haemostasis persists over 24 hours following a single intravenous dose of the drug. In addition to edoxaban, it also reverses the actions of LMWH and dabigatran.
Pharmacology
Mechanism of action
According to in vitro studies, the substance binds directly to anticoagulants via hydrogen bonds and charge-charge interactions from or to various parts of the molecule:
Hydrogen bonds | Rivaroxaban | Apixaban | Edoxaban | Dabigatran | Heparins |
---|---|---|---|---|---|
Guanidine part | Y | Y | Y | Y | |
α-Amino group | Y | Y | Y | Y | |
Amide nitrogen | Y | Y | Y | ||
Amide oxygen | Y | Y |
Chemistry
Ciraparantag consists of two L-arginine units connected with a piperazine containing linker chain.
See also
References
- ^ Schubert-Zsilavecz M, Wurglics M (Fall 2015). Neue Arzneimittel (in German).
- Ansell JE (February 2016). "Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants". Journal of Thrombosis and Thrombolysis. 41 (2): 248–52. doi:10.1007/s11239-015-1288-1. PMID 26449414. S2CID 7364744.
- ^ Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso MA, Brown K, et al. (January 2017). "Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban". Thrombosis and Haemostasis. 117 (2): 238–245. doi:10.1160/TH16-03-0224. PMC 6260118. PMID 27853809.
- Laulicht B, Bakhru S, Jiang X, Chen L, Pan D, Grosso M, Morishima Y, Brown K, Masumoto H, Costin J, Steiner S (June 2013). "Antidote for new oral anticoagulants: mechanism of action and binding specificity of PER977". J Thromb Haemost. 11 (suppl 2): 1–84.
- Costin JC, Laulicht B, Bakhru S, Steiner S (March 2015). "PER977 reverses low molecular weight heparin in addition to IIa and Xa new oral anticoagulants". Journal of the American College of Cardiology. 65 (10): A2056. doi:10.1016/S0735-1097(15)62056-3.
This drug article relating to the blood and blood forming organs is a stub. You can help Misplaced Pages by expanding it. |